Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.

Sebastian M, Schröder A, Scheel B, Hong HS, Muth A, von Boehmer L, Zippelius A, Mayer F, Reck M, Atanackovic D, Thomas M, Schneller F, Stöhlmacher J, Bernhard H, Gröschel A, Lander T, Probst J, Strack T, Wiegand V, Gnad-Vogt U, Kallen KJ, Hoerr I, von der Muelbe F, Fotin-Mleczek M, Knuth A, Koch SD.

Cancer Immunol Immunother. 2019 Feb 15. doi: 10.1007/s00262-019-02315-x. [Epub ahead of print]

PMID:
30770959
2.

The role of surface molecule CD229 in Multiple Myeloma.

Olson M, Radhakrishnan SV, Luetkens T, Atanackovic D.

Clin Immunol. 2018 Oct 13. pii: S1521-6616(18)30568-0. doi: 10.1016/j.clim.2018.10.006. [Epub ahead of print] Review.

PMID:
30326256
3.

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors.

Kebenko M, Goebeler ME, Wolf M, Hasenburg A, Seggewiss-Bernhardt R, Ritter B, Rautenberg B, Atanackovic D, Kratzer A, Rottman JB, Friedrich M, Vieser E, Elm S, Patzak I, Wessiepe D, Stienen S, Fiedler W.

Oncoimmunology. 2018 Apr 18;7(8):e1450710. doi: 10.1080/2162402X.2018.1450710. eCollection 2018.

4.

Pooled study of occupational exposure to aromatic hydrocarbon solvents and risk of multiple myeloma.

De Roos AJ, Spinelli J, Brown EB, Atanackovic D, Baris D, Bernstein L, Bhatti P, Camp NJ, Chiu BC, Clavel J, Cozen W, De Sanjosé S, Dosman JA, Hofmann JN, McLaughlin JR, Miligi L, Monnereau A, Orsi L, Purdue MP, Schinasi LH, Tricot GJ, Wang SS, Zhang Y, Birmann BM, Cocco P.

Occup Environ Med. 2018 Nov;75(11):798-806. doi: 10.1136/oemed-2018-105154. Epub 2018 Aug 18.

PMID:
30121582
5.

Biomarkers for checkpoint inhibition in hematologic malignancies.

Atanackovic D, Luetkens T.

Semin Cancer Biol. 2018 Oct;52(Pt 2):198-206. doi: 10.1016/j.semcancer.2018.05.005. Epub 2018 Jun 18. Review.

PMID:
29775689
6.

Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma.

Wei X, Calvo-Vidal MN, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V, Snyder C, Vachon CM, McKay JD, Wang SP, Jayabalan DS, Jacobs LM, Becirovic D, Waller RG, Artomov M, Viale A, Patel J, Phillip J, Chen-Kiang S, Curtin K, Salama M, Atanackovic D, Niesvizky R, Landgren O, Slager SL, Godley LA, Churpek J, Garber JE, Anderson KC, Daly MJ, Roeder RG, Dumontet C, Lynch HT, Mullighan CG, Camp NJ, Offit K, Klein RJ, Yu H, Cerchietti L, Lipkin SM.

Cancer Res. 2018 May 15;78(10):2747-2759. doi: 10.1158/0008-5472.CAN-17-1900. Epub 2018 Mar 20.

PMID:
29559475
7.

Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk.

Waller RG, Darlington TM, Wei X, Madsen MJ, Thomas A, Curtin K, Coon H, Rajamanickam V, Musinsky J, Jayabalan D, Atanackovic D, Rajkumar SV, Kumar S, Slager S, Middha M, Galia P, Demangel D, Salama M, Joseph V, McKay J, Offit K, Klein RJ, Lipkin SM, Dumontet C, Vachon CM, Camp NJ.

PLoS Genet. 2018 Feb 1;14(2):e1007111. doi: 10.1371/journal.pgen.1007111. eCollection 2018 Feb.

8.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kang Y, Kassim A, Liedtke M, Malek E, Martin T, Neppalli VT, Omel J, Raje N, Singhal S, Somlo G, Stockerl-Goldstein K, Weber D, Yahalom J, Kumar R, Shead DA.

J Natl Compr Canc Netw. 2018 Jan;16(1):11-20. doi: 10.6004/jnccn.2018.0002.

PMID:
29295877
9.

Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma.

Atanackovic D, Luetkens T, Radhakrishnan S, Kroger N.

Curr Cancer Drug Targets. 2017;17(9):839-845. doi: 10.2174/1568009617666170906170348. Review.

PMID:
28875836
10.

Novel anti-myeloma immunotherapies targeting the SLAM family of receptors.

Radhakrishnan SV, Bhardwaj N, Luetkens T, Atanackovic D.

Oncoimmunology. 2017 Mar 28;6(5):e1308618. doi: 10.1080/2162402X.2017.1308618. eCollection 2017. Review.

11.

Elotuzumab as a novel anti-myeloma immunotherapy.

Radhakrishnan SV, Bhardwaj N, Steinbach M, Weidner J, Luetkens T, Atanackovic D.

Hum Vaccin Immunother. 2017 Aug 3;13(8):1751-1757. doi: 10.1080/21645515.2017.1327487. Epub 2017 Jun 12. Review.

12.

Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation.

Templin J, Atanackovic D, Hasche D, Radhakrishnan SV, Luetkens T.

Oncotarget. 2017 Jul 25;8(30):49253-49263. doi: 10.18632/oncotarget.17534.

13.

An Anti-Programmed Death-1 Antibody (αPD-1) Fusion Protein That Self-Assembles into a Multivalent and Functional αPD-1 Nanoparticle.

Zhao P, Atanackovic D, Dong S, Yagita H, He X, Chen M.

Mol Pharm. 2017 May 1;14(5):1494-1500. doi: 10.1021/acs.molpharmaceut.6b01021. Epub 2017 Apr 19.

14.

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Liedtke M, Martin T, Omel J, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2017 Feb;15(2):230-269.

PMID:
28188192
15.

Current Strategies for the Immunotherapy of Multiple Myeloma.

Luetkens T, Yousef S, Radhakrishnan SV, Atanackovic D.

Oncology (Williston Park). 2017 Jan 15;31(1):55-63. Review.

16.

Immunotherapies targeting CD38 in Multiple Myeloma.

Atanackovic D, Steinbach M, Radhakrishnan SV, Luetkens T.

Oncoimmunology. 2016 Aug 5;5(11):e1217374. doi: 10.1080/2162402X.2016.1217374. eCollection 2016. Review.

17.

Acute effects of exercise on the inflammatory state in patients with idiopathic pulmonary arterial hypertension.

Harbaum L, Renk E, Yousef S, Glatzel A, Lüneburg N, Hennigs JK, Oqueka T, Baumann HJ, Atanackovic D, Grünig E, Böger RH, Bokemeyer C, Klose H.

BMC Pulm Med. 2016 Nov 11;16(1):145.

18.

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.

Rand KA, Song C, Dean E, Serie DJ, Curtin K, Sheng X, Hu D, Huff CA, Bernal-Mizrachi L, Tomasson MH, Ailawadhi S, Singhal S, Pawlish K, Peters ES, Bock CH, Stram A, Van Den Berg DJ, Edlund CK, Conti DV, Zimmerman T, Hwang AE, Huntsman S, Graff J, Nooka A, Kong Y, Pregja SL, Berndt SI, Blot WJ, Carpten J, Casey G, Chu L, Diver WR, Stevens VL, Lieber MR, Goodman PJ, Hennis AJ, Hsing AW, Mehta J, Kittles RA, Kolb S, Klein EA, Leske C, Murphy AB, Nemesure B, Neslund-Dudas C, Strom SS, Vij R, Rybicki BA, Stanford JL, Signorello LB, Witte JS, Ambrosone CB, Bhatti P, John EM, Bernstein L, Zheng W, Olshan AF, Hu JJ, Ziegler RG, Nyante SJ, Bandera EV, Birmann BM, Ingles SA, Press MF, Atanackovic D, Glenn MJ, Cannon-Albright LA, Jones B, Tricot G, Martin TG, Kumar SK, Wolf JL, Deming Halverson SL, Rothman N, Brooks-Wilson AR, Rajkumar SV, Kolonel LN, Chanock SJ, Slager SL, Severson RK, Janakiraman N, Terebelo HR, Brown EE, De Roos AJ, Mohrbacher AF, Colditz GA, Giles GG, Spinelli JJ, Chiu BC, Munshi NC, Anderson KC, Levy J, Zonder JA, Orlowski RZ, Lonial S, Camp NJ, Vachon CM, Ziv E, Stram DO, Hazelett DJ, Haiman CA, Cozen W.

Cancer Epidemiol Biomarkers Prev. 2016 Dec;25(12):1609-1618. Epub 2016 Sep 1.

19.

Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium.

Schinasi LH, Brown EE, Camp NJ, Wang SS, Hofmann JN, Chiu BC, Miligi L, Beane Freeman LE, de Sanjose S, Bernstein L, Monnereau A, Clavel J, Tricot GJ, Atanackovic D, Cocco P, Orsi L, Dosman JA, McLaughlin JR, Purdue MP, Cozen W, Spinelli JJ, de Roos AJ.

Br J Haematol. 2016 Oct;175(1):87-101. doi: 10.1111/bjh.14199. Epub 2016 Jun 22.

20.

Characterization of different CTC subpopulations in non-small cell lung cancer.

Hanssen A, Wagner J, Gorges TM, Taenzer A, Uzunoglu FG, Driemel C, Stoecklein NH, Knoefel WT, Angenendt S, Hauch S, Atanackovic D, Loges S, Riethdorf S, Pantel K, Wikman H.

Sci Rep. 2016 Jun 15;6:28010. doi: 10.1038/srep28010.

21.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2016 Apr;14(4):389-400.

22.

Integrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study.

Creutzfeldt A, Suling A, Oechsle K, Mehnert A, Atanackovic D, Kripp M, Arnold D, Stein A, Quidde J.

BMC Palliat Care. 2016 Mar 1;15:25. doi: 10.1186/s12904-016-0101-z.

23.

Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.

Atanackovic D, Radhakrishnan SV, Bhardwaj N, Luetkens T.

Br J Haematol. 2016 Mar;172(5):685-98. doi: 10.1111/bjh.13889. Epub 2016 Jan 20. Review.

PMID:
26791002
24.

Corrigendum: Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.

Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, Dumontet C, Dudziński M, Fejerman L, Greenberg A, Huntsman S, Jamroziak K, Jurczyszyn A, Kumar S, Atanackovic D, Glenn M, Cannon-Albright LA, Jones B, Lee A, Marques H, Martin T, Martinez-Lopez J, Rajkumar V, Sainz J, Juul Vangsted A, Watek M, Wolf J, Slager S, Camp NJ, Canzian F, Vachon C.

Nat Commun. 2015 Dec 9;6:10203. doi: 10.1038/ncomms10203. No abstract available.

25.

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2015 Nov;13(11):1398-435.

26.

A Pooled Analysis of Reproductive Factors, Exogenous Hormone Use, and Risk of Multiple Myeloma among Women in the International Multiple Myeloma Consortium.

Costas L, Lambert BH, Birmann BM, Moysich KB, De Roos AJ, Hofmann JN, Baris D, Wang SS, Camp NJ, Tricot G, Atanackovic D, Brennan P, Cocco P, Nieters A, Becker N, Maynadié M, Foretová L, Boffetta P, Staines A, Brown EE, de Sanjosé S.

Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):217-21. doi: 10.1158/1055-9965.EPI-15-0953. Epub 2015 Oct 13.

27.

Cancer-testis antigen MAGEC2 promotes proliferation and resistance to apoptosis in Multiple Myeloma.

Lajmi N, Luetkens T, Yousef S, Templin J, Cao Y, Hildebrandt Y, Bartels K, Kröger N, Atanackovic D.

Br J Haematol. 2015 Dec;171(5):752-62. doi: 10.1111/bjh.13762. Epub 2015 Oct 12.

PMID:
26456863
28.

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.

Stein A, Atanackovic D, Hildebrandt B, Stübs P, Brugger W, Hapke G, Steffens CC, Illerhaus G, Bluemner E, Stöhlmacher J, Bokemeyer C.

Br J Cancer. 2015 Sep 15;113(6):872-7. doi: 10.1038/bjc.2015.299. Epub 2015 Sep 3.

29.

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer.

Pujol JL, Vansteenkiste JF, De Pas TM, Atanackovic D, Reck M, Thomeer M, Douillard JY, Fasola G, Potter V, Taylor P, Bosquée L, Scheubel R, Jarnjak S, Debois M, de Sousa Alves P, Louahed J, Brichard VG, Lehmann FF.

J Thorac Oncol. 2015 Oct;10(10):1458-67. doi: 10.1097/JTO.0000000000000653.

30.

Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.

Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, Dumontet C, Dudziński M, Fejerman L, Greenberg A, Huntsman S, Jamroziak K, Jurczyszyn A, Kumar S, Atanackovic D, Glenn M, Cannon-Albright LA, Jones B, Lee A, Marques H, Martin T, Martinez-Lopez J, Rajkumar V, Sainz J, Vangsted AJ, Wątek M, Wolf J, Slager S, Camp NJ, Canzian F, Vachon C.

Nat Commun. 2015 Jul 22;6:7539. doi: 10.1038/ncomms8539. Erratum in: Nat Commun. 2015;6:10203.

31.

Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma.

Yousef S, Heise J, Lajmi N, Bartels K, Kröger N, Luetkens T, Atanackovic D.

J Transl Med. 2015 Jun 20;13:197. doi: 10.1186/s12967-015-0562-5.

32.

CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma.

Yousef S, Kovacsovics-Bankowski M, Salama ME, Bhardwaj N, Steinbach M, Langemo A, Kovacsovics T, Marvin J, Binder M, Panse J, Kröger N, Luetkens T, Atanackovic D.

Hum Vaccin Immunother. 2015;11(7):1606-11. doi: 10.1080/21645515.2015.1046658.

33.

A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer.

Bokemeyer C, Stein A, Ridwelski K, Atanackovic D, Arnold D, Wöll E, Ulrich A, Fischer R, Krüger C, Schuhmacher C.

Gastric Cancer. 2015 Oct;18(4):833-42. doi: 10.1007/s10120-014-0423-6. Epub 2014 Sep 12.

PMID:
25214034
34.

FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells.

Braga WM, da Silva BR, de Carvalho AC, Maekawa YH, Bortoluzzo AB, Rizzatti EG, Atanackovic D, Colleoni GW.

Cancer Immunol Immunother. 2014 Nov;63(11):1189-97. doi: 10.1007/s00262-014-1589-9. Epub 2014 Aug 7.

35.

Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation.

Luetkens T, Kobold S, Cao Y, Ristic M, Schilling G, Tams S, Bartels BM, Templin J, Bartels K, Hildebrandt Y, Yousef S, Marx A, Haag F, Bokemeyer C, Kröger N, Atanackovic D.

Cancer Immunol Immunother. 2014 Nov;63(11):1151-62. doi: 10.1007/s00262-014-1588-x. Epub 2014 Jul 31.

PMID:
25078248
36.

Is there any relationship between gene expression of tumor antigens and CD4+ T cells in multiple myeloma?

Braga WM, da Silva BR, Alves VL, Bortoluzo AB, Atanackovic D, Colleoni GW.

Immunotherapy. 2014;6(5):569-75. doi: 10.2217/imt.14.24.

PMID:
24896625
37.

5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity.

Stübig T, Badbaran A, Luetkens T, Hildebrandt Y, Atanackovic D, Binder TM, Fehse B, Kröger N.

Mediators Inflamm. 2014;2014:418292. doi: 10.1155/2014/418292. Epub 2014 Mar 13.

38.

Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer.

Laban S, Atanackovic D, Luetkens T, Knecht R, Busch CJ, Freytag M, Spagnoli G, Ritter G, Hoffmann TK, Knuth A, Sauter G, Wilczak W, Blessmann M, Borgmann K, Muenscher A, Clauditz TS.

Int J Cancer. 2014 Sep 1;135(5):1142-52. doi: 10.1002/ijc.28752. Epub 2014 Feb 11.

39.

Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity.

Harbaum L, Marx A, Goekkurt E, Schafhausen P, Atanackovic D.

Int J Hematol. 2014 Jan;99(1):91-4. doi: 10.1007/s12185-013-1474-x. Epub 2013 Nov 22.

PMID:
24264834
40.

Second autologous transplant as salvage therapy in multiple myeloma.

Atanackovic D, Schilling G.

Br J Haematol. 2013 Dec;163(5):565-72. doi: 10.1111/bjh.12579. Epub 2013 Sep 24. Review.

PMID:
24111632
41.

Immune-modulating drugs and hypomethylating agents to prevent or treat relapse after allogeneic stem cell transplantation.

Kröger N, Stübig T, Atanackovic D.

Biol Blood Marrow Transplant. 2014 Feb;20(2):168-72. doi: 10.1016/j.bbmt.2013.09.009. Epub 2013 Sep 22. Review.

42.

The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting.

Atanackovic D, Reinhard H, Meyer S, Spöck S, Grob T, Luetkens T, Yousef S, Cao Y, Hildebrandt Y, Templin J, Bartels K, Lajmi N, Stoiber H, Kröger N, Atz J, Seimetz D, Izbicki JR, Bokemeyer C.

Hum Vaccin Immunother. 2013 Dec;9(12):2533-42. doi: 10.4161/hv.26065. Epub 2013 Aug 16.

43.

CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives.

Berger LA, Riesenberg H, Bokemeyer C, Atanackovic D.

Lung Cancer. 2013 Jun;80(3):242-8. doi: 10.1016/j.lungcan.2013.02.004. Epub 2013 Feb 27. Review.

PMID:
23453646
44.

Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy.

Berdien B, Reinhard H, Meyer S, Spöck S, Kröger N, Atanackovic D, Fehse B.

Hum Vaccin Immunother. 2013 Jun;9(6):1205-16. doi: 10.4161/hv.24051. Epub 2013 Feb 21.

45.

Acute psychological stress increases peripheral blood CD3+CD56+ natural killer T cells in healthy men: possible implications for the development and treatment of allergic and autoimmune disorders.

Atanackovic D, Nowottne U, Freier E, Weber CS, Meyer S, Bartels K, Hildebrandt Y, Cao Y, Kröger N, Brunner-Weinzierl MC, Bokemeyer C, Deter HC.

Stress. 2013 Jul;16(4):421-8. doi: 10.3109/10253890.2013.777702. Epub 2013 Apr 8.

PMID:
23425210
46.

Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer.

Grob TJ, Hoenig T, Clauditz TS, Atanackovic D, Koenig AM, Vashist YK, Klose H, Simon R, Pantel K, Izbicki JR, Bokemeyer C, Sauter G, Wilczak W.

Lung Cancer. 2013 Mar;79(3):221-7. doi: 10.1016/j.lungcan.2012.11.009. Epub 2012 Dec 10.

PMID:
23238037
47.

Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.

Wolschke C, Stübig T, Hegenbart U, Schönland S, Heinzelmann M, Hildebrandt Y, Ayuk F, Atanackovic D, Dreger P, Zander A, Kröger N.

Exp Hematol. 2013 Feb;41(2):134-142.e3. doi: 10.1016/j.exphem.2012.10.004. Epub 2012 Oct 17.

PMID:
23085463
48.

Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.

Kröger N, Badbaran A, Zabelina T, Ayuk F, Wolschke C, Alchalby H, Klyuchnikov E, Atanackovic D, Schilling G, Hansen T, Schwarz S, Heinzelmann M, Zeschke S, Bacher U, Stübig T, Fehse B, Zander AR.

Biol Blood Marrow Transplant. 2013 Mar;19(3):398-404. doi: 10.1016/j.bbmt.2012.10.008. Epub 2012 Oct 16.

49.

Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung.

Grob TJ, Kannengiesser I, Tsourlakis MC, Atanackovic D, Koenig AM, Vashist YK, Klose H, Marx AH, Koops S, Simon R, Izbicki JR, Bokemeyer C, Sauter G, Wilczak W.

Mod Pathol. 2012 Dec;25(12):1566-73. doi: 10.1038/modpathol.2012.125. Epub 2012 Aug 17.

50.

Role of interleukin 16 in multiple myeloma.

Atanackovic D, Hildebrandt Y, Templin J, Cao Y, Keller C, Panse J, Meyer S, Reinhard H, Bartels K, Lajmi N, Sezer O, Zander AR, Marx AH, Uhlig R, Zustin J, Bokemeyer C, Kröger N.

J Natl Cancer Inst. 2012 Jul 3;104(13):1005-20. doi: 10.1093/jnci/djs257. Epub 2012 Jun 28.

PMID:
22745469

Supplemental Content

Loading ...
Support Center